NCT05723718

Brief Summary

The aim of this single-arm prospective, multicenter, cross-sectional study is to evaluate the nutritional status and body composition on tumor regression grade with bioelectrical impedance analysis in gastric cancer patients undergoing multimodal treatment. Results of this study will reveal whether nutritional status and body composition assessment based on bioelectrical impedance analysis will become a validated and objective tool to support clinical decisions in gastric cancer patients undergoing multimodal treatment.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
125

participants targeted

Target at P50-P75 for all trials

Timeline
32mo left

Started Dec 2022

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress56%
Dec 2022Dec 2028

Study Start

First participant enrolled

December 20, 2022

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

January 24, 2023

Completed
20 days until next milestone

First Posted

Study publicly available on registry

February 13, 2023

Completed
5.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2028

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2028

Last Updated

February 13, 2023

Status Verified

February 1, 2023

Enrollment Period

6 years

First QC Date

January 24, 2023

Last Update Submit

February 9, 2023

Conditions

Keywords

gastric cancerbioelectrical impedance analysisbody compositionnutritional statusmalnutritioncachexiamultimodal treatmenttumor regression grade

Outcome Measures

Primary Outcomes (1)

  • Tumor Regression Grade

    determined using the Becker criteria (1- complete response, 2 - good response, 3 - partial response, 4 - no response)

    Up to 2-4 weeks after the surgery

Secondary Outcomes (4)

  • Neoadjuvant Chemotherapy Toxicity

    From date of inclusion up to 1-3 months after the date of the first neoadjuvant chemotherapy cycle

  • Postoperative Complications

    From date of surgery, assessed up to 90 days

  • Overall Survival

    From from the date of surgery to the date of patient death or the date of the last follow-up - up to 10 years

  • Quality of Life score

    From date of inclusion through study completion - an average of 3 years

Interventions

Evaluation of the nutritional status and body composition on tumor regression grade in gastric cancer patients scheduled for multimodal treatment. Nutritional status assessment will include: selected clinical variables evaluation (weight, BMI, nutritional status scales), bioelectrical impedance analysis and selected laboratory parameter assessment. After inclusion in the study, each patient will have four consecutive nutritional status assessments: (1) one day prior staging laparoscopy or during qualification to neoadjuvant chemotherapy, (2) one day before the gastrectomy, (3) one month after the gastrectomy, (4) after the last cycle of adjuvant chemotherapy.

Also known as: Nutritional Status and Body Composition Assessment

Eligibility Criteria

Age18 Years - 100 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

This study will include a western population of patients with histologically confirmed, potentially curative esophageal gastro junction and gastric adenocarcinoma scheduled for multimodal treatment.

You may qualify if:

  • Age ≥ 18 years
  • Histologically confirmed gastric adenocarcinoma (or undifferentiated carcinoma)
  • Stage II - III disease (cT2 cN+ and cT3-T4 cN+/-) based on the 8th edition of TNM classification
  • Qualification for multimodal treatment by the decision of the multidisciplinary tumor board

You may not qualify if:

  • Early gastric cancer (cT1N0-3M0) scheduled for endoscopic treatment by multidisciplinary team
  • Gastric stump carcinoma
  • Distant metastasis
  • Upfront surgery
  • Other malignancies
  • Contraindications to bioelectrical impedance analysis (e.g., implanted cardiac devices, metal implants or pregnancy)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Medical University of Lublin

Lublin, 20-080, Poland

RECRUITING

Related Publications (1)

  • Pelc Z, Sedlak K, Mlak R, Chawrylak K, Mielniczek K, Lesniewska M, Skorzewska M, Kwietniewska M, Pasnik I, Geca K, van der Sluis P, Banasiewicz T, Pedziwiatr M, Polkowski WP, Pawlik TM, Malecka-Massalska T, Rawicz-Pruszynski K. MalnutritiOn assessment with biOelectrical impedaNce analysis in gastRic cancer patIentS undergoing multimodaltrEatment (MOONRISE)-Study protocol for a single-arm multicenter cross-sectional longitudinal study. PLoS One. 2024 Feb 6;19(2):e0297583. doi: 10.1371/journal.pone.0297583. eCollection 2024.

MeSH Terms

Conditions

Stomach NeoplasmsMalnutritionCachexia

Interventions

Nutritional Status

Condition Hierarchy (Ancestors)

Gastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesStomach DiseasesNutrition DisordersNutritional and Metabolic DiseasesWeight LossBody Weight ChangesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsThinness

Intervention Hierarchy (Ancestors)

Nutritional Physiological PhenomenaDiet, Food, and NutritionPhysiological PhenomenaHealth StatusDemographyPopulation Characteristics

Study Officials

  • Zuzanna Pelc, PhD

    Medical University of Lublin

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Zuzanna Pelc, PhD

CONTACT

Karol Rawicz-Pruszyński, Professor

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 24, 2023

First Posted

February 13, 2023

Study Start

December 20, 2022

Primary Completion (Estimated)

December 31, 2028

Study Completion (Estimated)

December 31, 2028

Last Updated

February 13, 2023

Record last verified: 2023-02

Locations